Table 1

Between group comparison of day 7 to baseline ratios for five hour urinary excretion of⁵¹CrEDTA/l-rhamnose (per protocol analysis)

	Day 7/baseline ratio for⁵¹CrEDTA/l-rhamnose	95% CI	p Value
Rofecoxib 25 mg vplacebo	0.82	0.65, 1.05^1-150	NS
Rofecoxib 50 mgv placebo	1.01	0.79, 1.29^1-150	NS
Indomethacin 150 mg vplacebo	1.58	1.22, 2.04	0.001
Indomethacin 150 mgv rofecoxib 25 mg	1.91	1.47, 2.48	<0.001
Indomethacin 150 mg vrofecoxib 50 mg	1.56	1.21, 2.01	0.001

↵1-150 Upper limit did not exceed 1.37 (that is, the upper 95% confidence interval for the rofecoxib vplacebo ⁵¹CrEDTA/l-rhamnose ratios).
NS, not significant.